Lentiviral-based CART-meso gene therapy / University of Pennsylvania - LARVOL DELTA

Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results (GlobeNewswire) - "Anticipated Milestones: VCN-01: (i) Initiation of VCN-01 dosing in an investigator sponsored study of brain tumors at the University of Leeds (H1 2022); (ii) Initiation of VCN-01 dosing in combination with mesothelin-directed CAR-T cells for pancreatic and ovarian cancer in an investigator sponsored study at the University of Pennsylvania (H1 2022); (iii) Initiation of a Phase 2 study of VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy in newly diagnosed metastatic PDAC patients (H2 2022); (iv) Initiation of a Phase 2/3 pivotal trial of VCN-01 as either an adjunct to chemotherapy or a potential rescue therapy in pediatric patients with advanced retinoblastoma (early 2023)."

New P2 trial • New P2/3 trial • New trial • Trial status • Brain Cancer • CNS Tumor • Eye Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Pancreatic Cancer • Retinoblastoma • Solid Tumor

Investigational CART-meso immunotherapy feasible for patients with advanced cancers (AACR) - P1, N=5; "Patients with advanced cancers who received chimeric antigen receptor-modified T cells (CART)-meso, a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood circulation and successfully migrated to the patients’ tumor sites, according to interim results from phase I clinical trial data presented here at the AACR Annual Meeting 2015, April 18-22."

Conference • P1 data • Oncology

CART-meso Long-term Follow-up (clinicaltrials.gov) - P=N/A; N=10; Completed; Sponsor: University of Pennsylvania; Active, not recruiting ➔ Completed; Trial completion date: Mar 2030 ➔ Jul 2019; Trial primary completion date: Mar 2030 ➔ Jul 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date